Difference between revisions of "Cyclosporine"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Media:" to "[[File:")
m
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
'''Note: this page contains information on multiple formulations of cyclosporine.'''
 
'''Note: this page contains information on multiple formulations of cyclosporine.'''
 
==General information==
 
==General information==
Class/mechanism: Cyclic polypeptide immunosuppressive agent that reversibly and preferentially inhibits T-lymphocytes, especially the T-helper cell. Exact mechanism unknown. Suppresses humoral immunity and cell-mediated immune reactions, including [[GVHD|graft vs. host disease]], allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, and Freund’s adjuvant arthritis. The Neoral formulation forms a microemulsion when present in an aqueous environment.
+
Class/mechanism: Cyclic polypeptide immunosuppressive agent that reversibly and preferentially inhibits T-lymphocytes, especially the T-helper cell. Exact mechanism unknown. Suppresses humoral immunity and cell-mediated immune reactions, including [[GVHD|graft vs. host disease]], allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, and Freund’s adjuvant arthritis. The Neoral formulation forms a microemulsion when present in an aqueous environment.
 
<br>Please choose from the products below to find specific drug/manufacturer information:  
 
<br>Please choose from the products below to find specific drug/manufacturer information:  
*Cyclosporine modified (Neoral)<ref>[http://www.neoral.com Neoral manufacturer's website]</ref><ref name="Neoral">[http://www.pharma.us.novartis.com/product/pi/pdf/neoral.pdf Cyclosporine modified (Neoral) package insert]</ref><ref>[[File:Cyclosporinemodified.pdf | Cyclosporine modified (Neoral) package insert (locally hosted backup)]]</ref>
+
*Cyclosporine modified (Neoral)<ref>[http://www.neoral.com Neoral manufacturer's website]</ref><ref name="Neoral">[http://www.pharma.us.novartis.com/product/pi/pdf/neoral.pdf Cyclosporine modified (Neoral) package insert]</ref><ref>[[:File:Cyclosporinemodified.pdf | Cyclosporine modified (Neoral) package insert (locally hosted backup)]]</ref>
*Cyclosporine modified (Gengraf)<ref>[http://www.gengraf.com/ Gengraf manufacturer's website]</ref><ref name="Gengraf">[http://www.rxabbott.com/pdf/gengraf-oral.pdf Cyclosporine modified (Gengraf oral) package insert]</ref><ref>[[File:Cyclosporinemodifiedgengraforal.pdf | Cyclosporine modified (Gengraf oral) package insert (locally hosted backup)]]</ref><ref>[http://www.rxabbott.com/pdf/gengraf-cap.pdf Cyclosporine modified (Gengraf capsule) package insert]</ref><ref>[[File:Cyclosporinemodifiedgengrafcapsule.pdf | Cyclosporine modified (Gengraf capsule) package insert (locally hosted backup)]]</ref>
+
*Cyclosporine modified (Gengraf)<ref>[http://www.gengraf.com/ Gengraf manufacturer's website]</ref><ref name="Gengraf">[http://www.rxabbott.com/pdf/gengraf-oral.pdf Cyclosporine modified (Gengraf oral) package insert]</ref><ref>[[:File:Cyclosporinemodifiedgengraforal.pdf | Cyclosporine modified (Gengraf oral) package insert (locally hosted backup)]]</ref><ref>[http://www.rxabbott.com/pdf/gengraf-cap.pdf Cyclosporine modified (Gengraf capsule) package insert]</ref><ref>[[:File:Cyclosporinemodifiedgengrafcapsule.pdf | Cyclosporine modified (Gengraf capsule) package insert (locally hosted backup)]]</ref>
*Cyclosporine non-modified (Sandimmune)<ref>[http://www.pharma.us.novartis.com/product/pi/pdf/sandimmune.pdf Cyclosporine non-modified (Sandimmune) package insert]</ref><ref>[[File:Cyclosporinenonmodified.pdf | Cyclosporine non-modified (Sandimmune) package insert (locally hosted backup)]]</ref>
+
*Cyclosporine non-modified (Sandimmune)<ref>[http://www.pharma.us.novartis.com/product/pi/pdf/sandimmune.pdf Cyclosporine non-modified (Sandimmune) package insert]</ref><ref>[[:File:Cyclosporinenonmodified.pdf | Cyclosporine non-modified (Sandimmune) package insert (locally hosted backup)]]</ref>
 
Route: IV, PO
 
Route: IV, PO
 
<br>Extravasation: no information
 
<br>Extravasation: no information
Line 22: Line 22:
 
*[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine non-modified (Sandimmune) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine non-modified (Sandimmune) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine non-modified (Sandimmune) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine non-modified (Sandimmune) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine modified (Neoral) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine modified (Neoral) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine modified (Neoral) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cyclosporine-systemic-patient-drug-information Cyclosporine modified (Neoral) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in PMDA indication==
 +
*2017-08-25: Revised indication and a new dosage for the treatment of [[aplastic anemia]] which is not severe.
  
 
==Also known as==
 
==Also known as==

Revision as of 01:18, 9 June 2023

Note: this page contains information on multiple formulations of cyclosporine.

General information

Class/mechanism: Cyclic polypeptide immunosuppressive agent that reversibly and preferentially inhibits T-lymphocytes, especially the T-helper cell. Exact mechanism unknown. Suppresses humoral immunity and cell-mediated immune reactions, including graft vs. host disease, allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, and Freund’s adjuvant arthritis. The Neoral formulation forms a microemulsion when present in an aqueous environment.
Please choose from the products below to find specific drug/manufacturer information:

Route: IV, PO
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

Patient drug information

History of changes in PMDA indication

  • 2017-08-25: Revised indication and a new dosage for the treatment of aplastic anemia which is not severe.

Also known as

  • Generic names: ciclosporin, CsA, CyA, cyclosporin, cyclosporin A
  • Brand names: Sandimmune, Gengraf, Neoral

References